References
- Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
- Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med 2002;346:1937–1947.
- Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991–9996.
- Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828–1837.
- Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol 2002;29:258–263.
- Nobili S, Napoli C, Puccini B, et al. Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. Leuk Lymphoma 2014;55:2071–2078.
- Pentheroudakis G, Goussia A, Voulgaris E, et al. High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. Leuk Lymphoma 2010;51:1260–1268.
- Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013;8:82–95.
- Leone S, Cornetta T, Basso E, et al. Resveratrol induces DNA double-strand breaks through human topoisomerase II interaction. Cancer Lett 2010;295:167–172.
- Thieblemont C, Rolland D, Baseggio L, et al. Comprehensive analysis of GST-pi expression in B-cell lymphomas: correlation with histological subtypes and survival. Leuk Lymphoma 2008;49: 1403–406.
- Musdal Y, Hegazy UM, Aksoy Y, et al. FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. Chem Biol Interact 2013;205:53–62.
- Hiddemann W, Longo DL, Coiffier B, et al. Lymphoma classification-the gap between biology and clinical management is closing. Blood 1996;88:4085–4089.